Indeed, Ag escape and induced adaptive resistance has also been reported in patients with recurrent glioblastoma who were treated with a single dose of CART cells redirected to the epidermal growth factor receptor variant III (EGFRvIII) mutation.4 The mechanism responsible for the appearance of Ag-loss variants is the immunoediting effect5 of monotarget therapies and the consequent immune selection of cancer cells expressing low or null target Ag levels. Here, RENBP is linked to glioblastoma.